US Patent 12076319 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
Patent 12076319 was granted and assigned to Achillion Pharmaceuticals on September, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+45 properties)
Article (+453 characters)
US Patent 12076319 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
Article
Patent abstract
Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Dharaben Patel0
Mingjun Huang0
Steven D. Podos0
Date of Patent
September 3, 2024
0Patent Application Number
167009100
Date Filed
December 2, 2019
0Patent Citations
0
Patent Primary Examiner
CPC Code
Find more entities like US Patent 12076319 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.